Elenbecestat - Biogen/Eisai
Alternative Names: E-2609Latest Information Update: 05 Nov 2023
At a glance
- Originator Eisai Inc
- Developer Biogen; Eisai Inc; GE Healthcare
- Class Antidementias; Small molecules
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 13 Sep 2019 Discontinued - Phase-I for Alzheimer's disease in USA (PO), after September 2019
- 13 Sep 2019 Discontinued - Phase-III for Alzheimer's disease (Early-stage disease) in China, Taiwan, South Africa, Slovakia, Singapore, Portugal, Mexico, Italy, Hungary, Finland, Denmark, Croatia, Chile, United Kingdom, Poland, South Korea, Greece, Germany, France, Czech Republic, Bulgaria, Canada, Australia, Argentina, Spain, Austria, Japan, USA (PO), after September 2019
- 13 Sep 2019 Eisai terminates a phase II trial in Alzheimer's disease in USA as a consequence of the discontinuation of MISSION AD1 and MISSION AD2 trials as per the recommendation of the Data Safety Monitoring Board (DSMB) due to unfavorable risk-benefit ratio (PO) (NCT02322021)